Pfizer and BioNTech said on Monday that the COVID-19 vaccine they developed together was 100 percent effective in protecting adolescents between the ages of 12 and 15.
In a statement quoted by The Hill, the two companies said the results from a long-term trial of 2,228 youth, measured from seven days through more than four months after the second dose, will form the basis for a planned supplemental application to the Food and Drug Administration (FDA) to expand approval of the vaccine for use in individuals in that age group.